PharmacoEconomics

, Volume 26, Issue 3, pp 181–183

Transparency of Economic Evaluations of Health Technologies

  • Joan Rovira
Editorial

References

  1. 1.
    Drummond MF. Economic evaluation of pharmaceuticals: science or marketing? Pharmacoeconomics 1992; 1: 8–13PubMedCrossRefGoogle Scholar
  2. 2.
    Antoñanzas F, Figueras M, Rovira J. Analysing the role of economic evaluation on decision-making in the health care system in Spain: a focus group approach. In: Gran von der Schulenburg JM, editor. The influence of economic evaluation studies on health care decision making. Amsterdam: IOS Press, 2000Google Scholar
  3. 3.
    Jacobs P, Bachynsky J, Baladi JF. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics 1995; 8: 182–9PubMedCrossRefGoogle Scholar
  4. 4.
    Reinhardt UE. Making economic evaluations respectable. Soc Sci Med 1997; 45: 555–62PubMedCrossRefGoogle Scholar
  5. 5.
    Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991; 324: 1362–5PubMedCrossRefGoogle Scholar
  6. 6.
    Task force on principles for economic analysis of economic analysis of health care technology: a report on principles. Ann Intern Med 1995; 123: 61-70Google Scholar
  7. 7.
    Kassirer JP, Angell M. The journal’s policy on cost-effectiveness analysis. N Engl J Med 1994; 331: 669–70PubMedCrossRefGoogle Scholar
  8. 8.
    Barbieri M, Drummond MF. Conflict of interest in industry-sponsored economic evaluations: real or imagined? Curr Oncol Rep 2001; 3: 410–3PubMedCrossRefGoogle Scholar
  9. 9.
    Sacristán JA, Bolaños E, Hernández JM, et al. Publication bias in health economics. Pharmacoeconomics 1997; 11: 289–91PubMedCrossRefGoogle Scholar
  10. 10.
    Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313 (7052): 275–83PubMedCrossRefGoogle Scholar
  11. 11.
    Jefferson T, Smith R, Yee Y, et al. Evaluating the BMJ guidelines for economic submissions: prospective audit of economic submissions to BMJ and the Lancet. JAMA 1998; 280: 275–7PubMedCrossRefGoogle Scholar
  12. 12.
    De Angelis C, Drazen JM, Frizelle FA, et al. International Committee of Medical Journal Editors. Editorial clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 2004; 351: 1250–1PubMedCrossRefGoogle Scholar
  13. 13.
    Smith R. Medical j ournals are an extension of the marketing arm of pharmaceutical companies. PLoS Med 2005; 2 (5): e 13 8CrossRefGoogle Scholar
  14. 14.
    Martinson BC, Anderson MS, De Vries R. Scientists behaving badly. Nature 2005; 435: 737–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Joan Rovira
    • 1
  1. 1.Department of EconomicsUniversity of BarcelonaBarcelonaSpain

Personalised recommendations